17 February 2022

COVID-19 TGA

New covid treatment options for immunocompromised patients

10 February 2022

COVID-19

How variant-proof are our covid treatments?

10 February 2022

COVID-19 Research

The year ahead in rheumatology

3 February 2022

COVID-19 Gout Lupus Scleroderma

Updated covid treatment guidelines and immunosuppressed patients

3 February 2022

COVID-19

Omicron wave crashes over hospitals

27 January 2022

COVID-19

Should boosters be delayed in covid patients?

27 January 2022

Comment COVID-19

We need to talk about masks

22 December 2021

COVID-19 Gout

Rheumatology Republic Year in Review

2 December 2021

APLAR COVID-19

AHPRA flexible on mandatory CPD training

25 November 2021

Biologics Comment COVID-19

Black Friday decision making, Covid and rituximab: is anyone buying?

25 November 2021

Corticosteroids COVID-19

Immunogenicity and benefits of third shot

18 November 2021

Biologics COVID-19

Cardiac toxicity risks with HCQ and CQ

8 November 2021

COVID-19 Pharmacy Guild of Australia Reactive Arthritis Technology

Day 2 conference highlights

7 November 2021

COVID-19

The role of rheumatology in the pandemic

4 November 2021

Conditions COVID-19

Vax safe even in people at high-risk of allergy

28 October 2021

APLAR COVID-19 Medications

TGA okays mix-and-match booster doses